In case there is any confusion, there is NO NEW PR regarding EUA. The trial site news article is a new article posting old news. And, Insightfulpenguin, I think you are confusing two separate PR's: the EUA announcement from September that used the 30 patient control and the "3-fold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement", and the more recent Oct 13 Topline Efficacy PR that compared the 24 control patients after 60 days, and a "9-fold increased probability of survival and recovery from respiratory failure, with a high degree of statistical significance".